Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advanced non-small-cell lung cancer (NSCLC) patients. A phase III trial was designed using an optimized immunization schedule. It included higher antigen dose and injections at multiple sites. Immune respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Popa, Xitlally, García, Beatriz, Fuentes, Karla P., Huerta, Vivian, Alvarez, Karen, Viada, Carmen E., Neninger, Elia, Rodríguez, Pedro C., González, Zuyen, González, Amnely, Crombet, Tania, Mazorra, Zaima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458606/
https://www.ncbi.nlm.nih.gov/pubmed/32923124
http://dx.doi.org/10.1080/2162402X.2020.1762465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458606/
https://www.ncbi.nlm.nih.gov/pubmed/32923124
http://dx.doi.org/10.1080/2162402X.2020.1762465

Ejemplares similares